Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.VYNE · Entity 6871 | Director | December 12, 2024 | December 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date December 12, 2024 · Filed December 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2034-12-11 | Direct | 20,000 |
Reported balance
After 2024-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-12 · Grant · Acquired 20,000 · Balance 20,000 F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-03-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-03-09 · Disposition to issuer · Disposed 62,647 · Balance 12,360 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Row 2 · 2020-03-09 · Disposition to issuer · Disposed 12,360 · Balance 0 F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2024 Filed Dec 13, 2024 16:15 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-24-029286 · form4-12132024_041207.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 17:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001209191-24-000461 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-31 F1 · derivative.exercise_date: The shares subject to the option vest on January 1, 2025, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 17:04 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-23-058811 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest on December 13, 2024, subject to the Reporting Person's continuous service through such date. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 17:11 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001209191-22-045650 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2032-08-10 F1 · derivative.exercise_date: Represents the annual award to non-executive directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. These options vest over a 12-month period in equal, monthly installments, ending August 10, 2023. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 17:05 UTC | Yarrow Bioscience, Inc. VYNE · Entity 6871 | GrantStock Options · Derivative | 20,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001209191-21-047410 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2031-07-19 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:39 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Options · Derivative | 22,500 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001209191-20-045130 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options vest over a 12 month period in equal, quarterly installments, ending August 3, 2021. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:21 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 14,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023803 · doc4.xml · nonDerivative · entry 2 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,056 F3 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:21 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 75,690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-023803 · doc4.xml · nonDerivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,123 F1 · price: As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) F2 · price: (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 16:44 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-20-020660 · doc4.xml · derivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 1/3rd of the shares subject to the option on each annual anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:55 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 7,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018223 · doc4.xml · nonDerivative · entry 2 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,433 F2 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:55 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantCommon Stock | 37,112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018223 · doc4.xml · nonDerivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,112 F1 · price: Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:37 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 12,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018193 · doc4.xml · nonDerivative · entry 2 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents Foamix restricted stock unit awards ("Foamix RSUs") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an "Adjusted RSU Award") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:37 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 62,647 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018193 · doc4.xml · nonDerivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,360 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 16:31 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 5,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015193 · doc4.xml · nonDerivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,007 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:41 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 28,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-031534 · doc4.xml · nonDerivative · entry 1 Bruno Anthony D · CIK 0001374180 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,695 F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · shares: The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.